business plans and objectives on the clinical development of clinical and preclinical pipeline, including the therapeutic potential, clinical benefits and safety thereof, Sanofi’s expansion of ...

Solid Biosciences has announced key updates from its clinical development pipeline, highlighting the administration of SGT-003 to four patients in the INSPIRE DUCHENNE trial for Duchenne muscular ...

Cerebral cavernous malformation (CCM) patients treated with oral drug, REC-994, showed reduction in total cerebral and brainstem lesion volume.

The phage therapy market is experiencing significant growth due to the increasing prevalence of antibiotic-resistant infections and the growing interest in alternative treatments. Advances in ...

Bio-Path Holdings announced significant advancements in its clinical development pipeline for 2025, including the exploration of its lead product, prexigebersen, in treating both acute myeloid ...

The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...

Xencor Inc . (NASDAQ:XNCR), a biopharmaceutical company specializing in innovative therapies for immunology and oncology, ...

Joseph Pantginis, an analyst from H.C. Wainwright, maintained the Buy rating on Tenaya Therapeutics (TNYA – Research Report). The associated price target remains the same with $18.00. Discover ...

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter” or the "Company”), a clinical-stage pharmaceutical company developing JOTROL ™, a patented resveratrol-based platform, today issued a statement ...

Arcus Biosciences, Inc. (NASDAQ:NYSE:RCUS), a biotechnology company focused on developing innovative cancer therapies, is navigating a critical phase in its development pipeline. With several key ...

ACLF clinical trials expected to initiate in 1Q253 clinical data readouts expected by year-end 2025 across the ACLF pipeline, including on-going UNVEIL-IT® Phase 2 trialData of on-going Phase 1b ...